目的 探讨消糖灵胶囊联合利拉鲁肽治疗肥胖2型糖尿病的临床疗效。方法 选择2019年12月—2021年6月在河北中石油中心医院治疗的120例肥胖2型糖尿病患者，随机分为对照组和治疗组，每组各60例。对照组早餐前皮下注射利拉鲁肽注射液，0.6 mg/次，1次/d。治疗组在对照组的基础上口服消糖灵胶囊，3片/次，2次/d。两组患者连续用药15周。观察两组患者临床疗效，比较治疗前后两组患者症状缓解时间，血糖指标空腹血糖（FPG）、餐后2 h血糖（2 h PBG）、糖化血红蛋白（HbA1c）和空腹血清胰岛素（FINS）水平，血清因子肿瘤坏死因子-α（TNF-α）、可溶性血管细胞黏附因子-1（Svcam-1）、白细胞介素-6（IL-6）和超敏C反应蛋白（hs-CRP）水平，及不良反应。结果 治疗后，治疗组总有效率为98.33%，明显高于对照组的83.33%（P<0.05）。治疗后，治疗组多饮、多食、多尿、口干缓解时间均明显早于对照组（P<0.05）。治疗后，两组患者FPG、2 h FPG、HbA1c、FINS指标和血清因子TNF-α、Svcam-1、IL-6、hs-CRP水平均明显下降（P<0.05），且治疗后治疗组这些指标明显低于对照组（P<0.05）。治疗期间，治疗组不良反应发生率为6.67%，明显低于对照组的13.33%（P<0.05）。结论 消糖灵胶囊联合利拉鲁肽治疗肥胖2型糖尿病效果确切，症状缓解明显，并能有效控制患者血糖，降低机体炎症反应。

Objective To discuss the treatment effect of Xiaotangling Capsules combined with liraglutide in treatment of obesity type 2 diabetes. Methods Patients (120 cases) with obesity type 2 diabetes in Hebei Petro China Central Hospital from December 2019 to June 2021 were randomly divided into control and treatment group, and each group had 60 cases. Patients in the control group were sc administered with Liraglutide Injection before breakfast, 0.6 mg/time, once daily. Patients in the treatment group were po administered with Xiaotangling Capsules on the basis of the control group, 3 tablets/time, twice daily. Patients in two groups were treated for 15 weeks. After treatment, the clinical evaluation was evaluated, the improvement time of symptoms, the levels of blood glucose indexes FBG, 2 h PBG, HbA1c, and FINS, the levels of TNF-α, Svcam-1, IL-6, and hs-CRP, and adverse reactions in two groups. Results After treatment, the clinical effective rate of the treatment group was 98.33%, which was significantly higher than that of the control group (83.33%, P < 0.05). After treatment, the relief time of polydipsia, polydipsia, polyuria, and dry mouth in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, the indexes FPG, 2 h FPG, HbA1c, FINS, and the levels of serum factor TNF-α, sVCAM-1, IL-6, and hs-CRP in two groups were significantly decreased (P < 0.05), and the indicators the treatment group were significantly lower than those in the control group (P < 0.05). During the treatment period, the incidence of adverse reactions in the treatment group was 6.67%, significantly lower than 13.33% in the control group (P < 0.05). Conclusion Xiaotangling Capsules combined with liraglutide is effective in treatment of obesity type 2 diabetes with obvious symptom relief, and can effectively control the patient's blood glucose, reduce the inflammatory response,.

R977

廊坊市科技支撑计划项目（2019013121）